Abiopharma

News list

Holder Michael 🟡 adjusted position in 0 shares (1 derivative) of Cytek Biosciences, Inc. (CTKB) Transaction Date: Mar 10, 2026 | Filing ID: 000001

Full text

News bot March 12, 2026, 8:35 p.m.
🔍 Holder Michael (Executive)

Company: Cytek Biosciences, Inc. (CTKB)

Report Date: 2026-03-10
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 0
- Total shares acquired: 2,908
- Total shares sold: 2,908
Detailed Transactions and Holdings:
- Acquired 2,908 shares of Common Stock (Direct)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,267.00 | transaction_form_type: 4 | Footnotes: F1
- Sold 2,908 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-10 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,911.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
Footnotes:
- F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2: 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested.